Live Breaking News & Updates on Peter Mac Cancer Center

Stay updated with breaking news from Peter mac cancer center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia

Initial Discussion Held with Clinical Investigator at Australia’s Biggest Cancer Hospital ....

United States , Mark Rosenthal , Peter Mac , James Nathanielsz , Company Mechanism Of Action , Peter Mac Cancer Center , Propanc Biopharma Inc , Drug Administration , Initial Discussion Held , Clinical Investigator , Biggest Cancer , Propanc Biopharma , Professor Mark Rosenthal , Study Investigator , Chief Executive , Australian Government , Advance Overseas Finding , Science Australia , Drug Designation , Private Securities Litigation Reform Act , Press Release ,

Sheba Medical Center Signs Agreement With Australian Cancer Center

Australia’s Peter MacCallum Cancer Centre and Israel’s Sheba Medical Centre want to foster new international research collaborations. ....

Arnon Afek , Peter Maccallum , Shelley Dolan , Avri Alfasi , Peter Mac , Australia Peter Maccallum Cancer Center , Australian Friends Of Sheba Medical Center , Innovation Center , Peter Mac Cancer Center , Peter Maccallum Cancer Center , Sheba Medical Center , Israel Sheba Medical Center At Tel Hashomer , Tel Hashomer , Maccallum Cancer Center , Medical Center , Australian Friends , Sheba Medical , Mac Chief Executive , Prof Shelley Dolan , Peter Chief Executive , Peter Mac Cancer ,

Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients

Press release content from Business Wire. The AP news staff was not involved in its creation.
Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients
January 18, 2021 GMT
MELBOURNE, Australia (BUSINESS WIRE) Jan 18, 2021
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers. The letters of interest were confirmed by Drs Natalia Luque Caro and Fernando Gálvez Montosa, medical oncologists specializing in pancreatic and ovarian cancers, respectively, from the University Hospital of Jaén, in Granada, Spain. The evaluation will most likely be conducted as separate P ....

Natalia Luque Caro , James Nathanielsz , Exchange Commission , Peter Mac Cancer Center , University Hospital Of Ja , Propanc Biopharma Inc , Company Registration Statement On Form , Company Mechanism Of Action , Drs Natalia Luque Caro , University Hospital , Drs Caro , Chief Executive , Propanc Biopharma , Registration Statement , Investor Relations , Media Contacts , Business Wire , Products And Services , Government Regulations , Pancreatic Cancer , Western Europe , Ovarian Cancer , Product Testing , Health Care Industry , New Products And Services , Women X27s Health ,